A Randomized, Open-Label, Assessor-Blinded, Split-Face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses.

Trial Profile

A Randomized, Open-Label, Assessor-Blinded, Split-Face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Imiquimod (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2010 Company added in the association field and additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 26 Mar 2010 Actual patient number (27) added as reported by ClinicalTrials.gov.
    • 26 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top